July 13, 2021 – Integra LifeSciences announced its SurgiMend Collagen Matrix for Soft Tissue Reconstruction has received an Innovative Technology contract from Vizient, Inc. (Irving, TX), according to a press release obtained by the Dail-eNews.
According to the company, SurgiMend is the only product derived from a bovine dermis source cleared by the U.S. FDA to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured tissue membranes including plastic and reconstructive surgery, hernia repair, and muscle flap reinforcement.
SurgiMend rapidly revascularizes to support tissue building for prolonged reinforcement, without eliciting a detrimental foreign body response. Additionally, SurgiMend has demonstrated low recurrence rates in primary fascial reinforcement of complex abdominal wound reconstruction (CAWR) patients up to six years post-implantation in multiple peer-reviewed journal articles since 2012.
The technology is available in a variety of unique configurations and thicknesses, including SurgiMend Macroporous (MP) and SurgiMend PRS Meshed.
“A product receives this type of contract when it demonstrates a unique quality that differentiates it from other products on the market,” said Debbie Archer, director of procurement and Vizient Innovative Technology Program leader. “Our member council determined that SurgiMend Collagen Matrix for Soft Tissue Reconstruction met this standard and recognizes its potential to improve quality outcomes.”